Apollo Therapeutics Revenue and Competitors

Location

#1304

Growjo Ranking

Biotech

Industry

Estimated Revenue & Valuation

  • Apollo Therapeutics's estimated annual revenue is currently $9.6M per year.(i)
  • Apollo Therapeutics's estimated revenue per employee is $155,000

Employee Data

  • Apollo Therapeutics has 62 Employees.(i)
  • Apollo Therapeutics grew their employee count by 55% last year.

Apollo Therapeutics's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
VP & Head Immunology & Inflammation Clinical DevelopmentReveal Email/Phone
3
Head FinanceReveal Email/Phone
4
Head Medicinal ChemistryReveal Email/Phone
5
Chief Financial OfficerReveal Email/Phone
6
Program DirectorReveal Email/Phone
7
Program DirectorReveal Email/Phone
8
Program DirectorReveal Email/Phone
9
Director CMCReveal Email/Phone
10
Chief Scientific OfficerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$81.4M37540%N/AN/A
#2
$16.9M10922%N/AN/A
#3
$156.1M120-70%$145MN/A
#4
$2.9M37-24%$150MN/A
#5
$1.3M170%$459.5MN/A
#6
$49.2M25415%$180.7MN/A
#7
$7M45-2%N/AN/A
#8
$256.3M8409%$168.5MN/A
#9
$4.2M27-7%N/AN/A
#10
$10.1M655%N/AN/A
Add Company

What Is Apollo Therapeutics?

keywords:N/A

N/A

Total Funding

62

Number of Employees

$9.6M

Revenue (est)

55%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Apollo Therapeutics News

2022-04-13 - Von Willebrand Disease (VWD) Therapeutics Market Analysis ...

Von Willebrand Disease (VWD) Therapeutics Market Analysis, Research Study With Apollo Therapeutics, Apotex, Bayer.

2022-04-06 - Full throttle': venture capital in 2021

“Now is the time to really accelerate it and go full throttle”, said Richard Butt, the Chief Scientific Officer at Apollo Therapeutics,...

2022-03-30 - APOLLO: SLN360 Clears First Major Hurdle, Hammering Lp(a)

... but with elevated Lp(a) in the small dose-ranging APOLLO trial. Following a single subcutaneous dose of SLN360 (Silence Therapeutics),...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$5.6M6213%N/A
#2
$3.5M623%N/A
#3
$15M625%N/A
#4
$8.1M625%N/A
#5
$9.8M62-9%N/A